- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04275726
LANDMARK Trial: a Randomised Controlled Trial of Myval THV (LANDMARK)
A Prospective, Multinational, Multicentre, Open-label, Randomised, Non-inferiority Trial to Compare Safety and Effectiveness of Meril's Myval Transcatheter Heart Valve (THV) Series vs. Contemporary Valves (Edwards's Sapien THV Series and Medtronic's Evolut THV Series) in Patients With Severe Symptomatic Native Aortic Valve Stenosis
The primary objective of this study (LANDMARK) is to compare the safety and effectiveness of the Myval THV Series with Contemporary Valves (Sapien THV Series and Evolut THV Series) in patients with severe symptomatic native aortic valve stenosis.
This study will be done in total 768 subjects (384:384, Myval THV Series vs. Contemporary Valves)
The randomisation will be carried out with an allocation ratio of 1:1 between Myval THV Series vs. Contemporary Valves (Sapien THV Series and Evolut THV Series)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
LANDMARK Trial is a prospective, randomised, multinational, multicentric, open-label non-inferiority trial of total 768 subjects (384:384, Myval THV Series vs. Contemporary Valves) with severe symptomatic native aortic valve stenosis via transfemoral approach.
- Device sizes applicable for the Myval THV Series: 20 mm, 21.5 mm, 23 mm, 24.5 mm, 26 mm, 27.5 mm, and 29 mm diameter.
- Device sizes applicable for the Sapien 3 THV Series: 20 mm, 23 mm, 26 mm, and 29 mm diameter.
- Device sizes applicable for the Evolut THV Series: 23 mm, 26 mm, 29 mm, and 34 mm diameter.
A non-randomised nested registry will be conducted to include patients requiring extra-large size of Myval THV series (XL Nested Registry)
- Device sizes applicable for the XL Nested Registry: 30.5 mm and 32 mm.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ashok Thakkar, PhD
- Phone Number: +91-9879443584
- Email: ashok.thakkar@merillife.com
Study Locations
-
-
-
Minsk, Belarus, 220036
- Not yet recruiting
- Republican Scientific-Practical Centre "Cardiology"
-
Contact:
- Dr. Oleg Polonetsky, MD, PhD
- Email: polonetsky@yandex.ru
-
-
-
-
-
São Paulo, Brazil, 04012-909
- Recruiting
- Hospital Dante Pazanesse
-
Contact:
- Dr. Fausto Feres
- Email: fferes@dantepazzanese.org.br
-
Sub-Investigator:
- Andrea Vilela,
-
Sub-Investigator:
- Dimytri Siqueira
-
-
-
-
-
Split, Croatia, 21000
- Recruiting
- Split Clinical Hospital Center
-
Contact:
- Dr. Ivica Kristic, MD, PhD
- Email: kristicivica@gmail.com
-
Zagreb, Croatia, 10000
- Recruiting
- University Hospital Dubrava Avenija Gojka Šuška 6
-
Contact:
- Dr. Daniel Unić, MD
- Phone Number: +385989196621
- Email: unic@kbd.hr
-
-
-
-
-
Tallinn, Estonia
- Recruiting
- North Estonia Medical Center
-
Contact:
- Dr. Peep Laanmets
-
-
-
-
-
Créteil, France, 94000
- Recruiting
- Hopital Henri Mondor
-
Contact:
- Prof. Emmanuel Teiger
- Email: emmanuel.teiger@aphp.fr
-
Lille, France, 59000
- Recruiting
- Lille University
-
Contact:
- Prof. Eric Van Belle
- Email: ericvanbelle@aol.com
-
Massy, France, 91300
- Recruiting
- Institut Cardiovascular Paris-Sud
-
Contact:
- Dr. Bernard Chevalier
- Email: bchevali@aol.com
-
Nice, France, 06200
- Recruiting
- Arnault Tzanck Institute
-
Contact:
- Dr. ADJEDJ Julien
- Email: juliendjdj@gmail.com
-
Rennes, France, 35033
- Not yet recruiting
- Centre Hospitalier Universitaire de Rennes
-
Contact:
- Dr. Vincent Auffret
- Email: vincent.auffret@chu-rennes.fr
-
-
-
-
-
Bad Krozingen, Germany, 79189
- Recruiting
- University Herzentrum Division of Cardiology and Angiology II,University Heart Center Freiburg, Südring 15
-
Contact:
- Dr. Jurgen Rothe
- Email: juergen.rothe@uniklinik-freiburg.de
-
Braunschweig, Germany, 38118
- Active, not recruiting
- Klinikum Braunschweig Freisestre
-
Dresden, Germany, 01307
- Recruiting
- Technology University Dresden Fetscherstraße 76
-
Contact:
- Prof. Dr. Axel Linke
- Email: Axel.Linke@herzzentrum-dresden.com
-
Hamburg, Germany, 20099
- Not yet recruiting
- Asklepios Kliniken Hamburg Gmbh Lohmuehlenstrasse 5
-
Contact:
- Dr. Samer Hakmi, MD
- Email: samer@hakmi.des.hakmi@asklepois.com
-
Regensburg, Germany, 93053
- Recruiting
- Klinik für Herz-, Thorax- und herznahe Gefäßchirurgie, Universitätsklinikum Regensburg
-
Contact:
- Dr. med. Andreas Holzamer
- Email: andreas.holzamer@klinik.uni-regensburg.de
-
Sub-Investigator:
- Prof. Dr. Med. Michael Hilker
-
-
Hesse
-
Bad Nauheim, Hesse, Germany, 61231
- Recruiting
- Kerckhoff-KlinikForschungs GmbH
-
Contact:
- Dr. Won K Kim, M.D
- Phone Number: +49 60326152
- Email: w.kim@kerckhoff-klinik.de
-
-
Saxony
-
Leipzig, Saxony, Germany, 04289
- Recruiting
- Leipzig Heart Institute GmbH
-
Contact:
- Prof Mohamed A Wahab, Ph. D
- Phone Number: +493418650
- Email: mohamed.abdel-wahab@medizin.uni-leipzig.de
-
-
-
-
-
Athens, Greece, 11527
- Recruiting
- Hippkration Hospital
-
Contact:
- Prof. Konstantinos Toutouzas
- Phone Number: +30 2132088026
- Email: ktoutouz@gmail.com
-
Maroúsi, Greece
- Recruiting
- Hygeia Hospital
-
Contact:
- Dr. Konstantinos Spargias
- Email: Spargiaskspargias@hygeia.gr
-
Thessaloniki, Greece, 555 35
- Recruiting
- Interbalkan European Medical Center
-
Contact:
- Dr. Vlasis Ninios
- Phone Number: +302310400929
- Email: vninios@gmail.com
-
-
-
-
-
Budapest, Hungary, 1122
- Recruiting
- Semmelweis University
-
Contact:
- Prof. Bela Merkely, MD Ph. D
- Phone Number: 36206632488
- Email: merkely.bela@kardio.sote.hu
-
Sub-Investigator:
- Dr. Roland Papp, MD
-
-
-
-
-
Bologna, Italy, 40141
- Not yet recruiting
- University of Bologna Policlinico S. Orsola-Malpigh
-
Contact:
- Dr. Francesco Saia
- Email: francescosaia@hotmail.com
-
Catania, Italy, 95100
- Not yet recruiting
- Policlinico di Catania
-
Contact:
- Dr. Corrado Tamburino
- Email: tambucor@unict.it
-
Milan, Italy, 20121-20162
- Recruiting
- San Donato Hospital
-
Contact:
- Dr. Francesco Bedogni
- Phone Number: + 39 335 5309117
- Email: Francesco.bedogni@grupposandonato.it
-
Milano, Italy, 20149
- Recruiting
- Clinical Institute Saint Ambrogio
-
Contact:
- Dr. Alfonso Ielasi
- Phone Number: +39 338 8433189
- Email: alielasi@hotmail.com
-
Milano, Italy, 20132
- Recruiting
- San Raffaele Hospital
-
Contact:
- Dr. Matteo Montorfano
- Phone Number: +39 02 26437331
- Email: montorfano.matteo@hsr.it
-
Sub-Investigator:
- Dr.BELLINI BARBARA
-
Tortona, Italy, 10128
- Not yet recruiting
- Mauriliano Hospital Largo Filippo
-
Contact:
- Prof. Dr. Giuseppe Musumeci
-
Turin, Italy, 10126
- Not yet recruiting
- University Hospital Città della Salute e della Scienza Turin Bramante
-
Contact:
- Prof Gaetano Maria De Ferrari
- Phone Number: 011 6334634
- Email: gaetanomaria.deferrari@unito.it
-
-
-
-
-
Amsterdam, Netherlands, 1091
- Active, not recruiting
- Onze lieve vrouwe gasthuis Oosterperk 9
-
Breda, Netherlands, 4817
- Recruiting
- Amphia Ziekenhui Hospital
-
Contact:
- Dr. A.J.J. Ijsselmuiden Sander
- Phone Number: +31(0)655814502
- Email: sander.ijsselmuiden@gmail.com
-
Groningen, Netherlands, 9713
- Not yet recruiting
- University Medical Center (UMC)
-
Contact:
- Dr. Joanna J Wykrzykowska
- Phone Number: +31-630367425
- Email: joannawykrzykowska70@gmail.com/ j.wykrzykowska@amsterdamumc.nl
-
Utrecht, Netherlands, 3584
- Recruiting
- University Medical Center Utrecht
-
Contact:
- Dr. Michiel Voskuil
- Email: mvoskuil@umcutrecht.nl
-
-
Dutch
-
Nieuwegein, Dutch, Netherlands, 3435
- Recruiting
- St Antonius hospital
-
Contact:
- Dr. B.J.W.M Rensing, Cardiologist
- Phone Number: +31 306093974
- Email: b.rensing@antoniusziekenhuis.nl
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6525 XZ
- Recruiting
- Radboud University Nijmegen
-
Contact:
- Prof. Niels V Royen, Ph.D
- Email: niels.vanroyen@radboudumc.nl
-
-
Overijssel
-
Zwolle, Overijssel, Netherlands, 8025 AB
- Active, not recruiting
- Isala Zwolle Hospital
-
-
-
-
Auckland
-
Grafton, Auckland, New Zealand, 1023
- Recruiting
- Auckland City Hospital 2 Park Road
-
Contact:
- Dr. Mark Webster, MD
- Phone Number: +64 9 307 4949
- Email: mwebster@adhb.govt.nz
-
-
-
-
-
Warsaw, Poland, 50-013
- Not yet recruiting
- Institute of Cardiology
-
Contact:
- Prof. Adam Witkowski, MD, PhD, FESC
- Phone Number: +48 22 812 41 64
- Email: witkowski@hbz.pl
-
Wrocław, Poland, 50-369
- Recruiting
- Uniwersytecki Szpital Kliniczny (USK) Curie-Skłodowskiej 58
-
Contact:
- Dr. Marcin Protasiewicz
- Phone Number: +48 71 7364200
- Email: marcin.protasiewicz@umed.wwroc.pl
-
-
Małopolskie Województwo
-
Krakow, Małopolskie Województwo, Poland, 31-202
- Not yet recruiting
- John Paul II Hospital
-
Contact:
- Dr n. med Jaroslaw Trebacz, MD PhD
-
-
Pomorskie Województwo
-
Gdańsk, Pomorskie Województwo, Poland, 80-952
- Not yet recruiting
- University of Gdansk
-
Contact:
- Prof. Darius Jageilak, MD PhD
- Phone Number: +48585844200
- Email: darjag@gumed.edu.pl
-
Sub-Investigator:
- Radoslaw Targonski, MD PhD
-
Sub-Investigator:
- Aleksandra Wierzbowska, MD
-
Sub-Investigator:
- Marcin Fijalkowski, PhD
-
-
Prussian
-
Katowice, Prussian, Poland, 40-635
- Not yet recruiting
- Medical University of Silesia
-
Contact:
- Dr. Wojciech Wojakowski, MD PhD
- Email: wwojakowski@sum.edu.pl
-
-
-
-
-
Carnaxide, Portugal, 2790-134
- Recruiting
- Centro Hospitalar Lisboa Ocidental EPE- Hospital Santa Cruz, Av. Prof. Dr. Reinaldo dos Santos
-
Contact:
- Dr. Manuel Almeida
- Phone Number: +351 936359285
- Email: almeidams@sapo.pt
-
Lisboa, Portugal, 1649-028
- Not yet recruiting
- Hospital de Santa Maria, Av. Prof. Egas Moniz MB
-
Contact:
- Dr. Pedro Carrilho Ferreira
- Phone Number: +351 966 412 473
- Email: pcarrilhoferreira@gmail.com
-
Lisbon, Portugal, 1169-024
- Recruiting
- Centro Hospital Lisboa Central E.P.E. - Santa Marta
-
Contact:
- Dr. Duarte Cacela
- Email: dcacela@hotmail.com
-
Porto, Portugal, 4200-319
- Not yet recruiting
- Centro Hospitalar de São João
-
Contact:
- Dr. Joao Carlos Silva, PhD
- Email: joaocebsilva@hotmail.com
-
-
-
-
-
Banská Bystrica, Slovakia, 975 17
- Recruiting
- University hospital Banska Bystrica Námestie Ludvíka Svobodu 1
-
Contact:
- Dr. Martin Hudec
- Phone Number: +421 918 106033
- Email: hudecmt@hotmail.com
-
-
-
-
-
Ljubljana, Slovenia, 1000
- Recruiting
- University Medical Center, Ljubljana
-
Contact:
- Prof. Matjaz Bunc, MD, PhD
- Phone Number: +38615225050
- Email: matjaz.bunc@kclj.si
-
-
-
-
-
Córdoba, Spain, 5000
- Recruiting
- Hospital Universitario Renei Sofia
-
Contact:
- Dr. Manuel Pan
- Email: manuelpanalvarez@gmail.com
-
Madrid, Spain, 28040
- Not yet recruiting
- Hospital Clinico San Carlos
-
Contact:
- Dr. Luis Nombela, MD, PhD
- Phone Number: +34629510139
- Email: luisnombela@yahoo.com
-
Valladolid, Spain, 47003
- Recruiting
- Hospital Cliinico Univertistario de Valladolid
-
Contact:
- Dr. Ignacio A Santos, Medicine & Surgery
- Phone Number: +34657923040
- Email: ijamat@gmail.com
-
Sub-Investigator:
- Dr. Juan Pablo Sánchez Luna, MD, PhD
-
-
Canary Islands
-
Las Palmas, Canary Islands, Spain, 35010
- Recruiting
- Hospital Universitario de Gran Canaria Dr Negrin
-
Contact:
- Dr. Pedro Martin Lorenzo
- Phone Number: +34928450000
- Email: pemarlor@hotmail.com
-
-
Illes Balears
-
Palma De Mallorca, Illes Balears, Spain, 07120
- Recruiting
- Hospital Universitari Son Espases Carretera de Valldemossa
-
Contact:
- Dr. Vicente Peral
- Phone Number: +34 871205381
- Email: vicente.peral@ssib.es
-
Sub-Investigator:
- Dr. Tania Rdgz Gabella
-
-
-
-
-
Göteborg, Sweden
- Recruiting
- Sahlgrenska University Hospital
-
Contact:
- Dr. Oskar Angreas
- Email: oskar.angeras@vgregion.se
-
Uppsala, Sweden
- Recruiting
- Uppsala University Hospital
-
Contact:
- Prof. Stefan James
- Email: stefan.james@ucr.uu.se
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient ≥18 years of age.
- Patient or their legal representative has provided written informed consent as approved by the Institutional Review Board (IRB)/Institutional Ethics Committee (IEC) of the investigational site to participate in the study.
- As per local Heart Team assessment, patient is eligible for TAVI and the patient is suitable for implantation with all three study devices.
Exclusion Criteria:
- Patients who are not willing to provide informed consent form, or whose legal heirs object to their participation in the study.
- Any condition, which in the Investigator's opinion, would preclude safe participation of patient in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Myval THV Series
Myval THV Series will include Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site. This treatment arm will be assigned to 384 / 768 subjects enrolled in a study. |
The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy.
Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
Other Names:
|
Active Comparator: Contemporary Valves
This treatment arm will be assigned to 384 / 768 subjects enrolled in a study. |
The devices in the study are intended to improve aortic valve function for patients with severe symptomatic native aortic valve stenosis who are eligible for TAVR therapy.
Every patient must be deemed treatable with an available size of both the test and contemporary heart valves approved for use and commercially available at the investigational centre where the implant procedure is being performed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Combined Safety and Effectiveness Endpoint as defined by the Valve Academic Research Consortium-3 (VARC-3)
Time Frame: 30-day
|
It is the composite of following:
|
30-day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional improvement from baseline as measured per
Time Frame: Baseline (within 30 days prior to index procedure), 30-day, 1-year, 3-year, 5-year, 7-year, and 10-year)
|
New York Heart Association (NYHA) functional classification
|
Baseline (within 30 days prior to index procedure), 30-day, 1-year, 3-year, 5-year, 7-year, and 10-year)
|
The combined safety and effectiveness endpoint as defined by the Valve Academic Research Consortium-3 (VARC-3)
Time Frame: 1-year
|
It is the composite of following:
|
1-year
|
All-cause mortality
Time Frame: Pre-discharge, 30-day, 6-month, 1-year, 2-year, 3-year, 4 year, 5-year, 7-year, and 10-year
|
As per VARC-3 defined criteria
|
Pre-discharge, 30-day, 6-month, 1-year, 2-year, 3-year, 4 year, 5-year, 7-year, and 10-year
|
All stroke
Time Frame: Pre-discharge, 30-day, 1-year, 3-year, and 5-year
|
As per VARC-3 defined criteria
|
Pre-discharge, 30-day, 1-year, 3-year, and 5-year
|
Acute Kidney Injury (AKI) (Stage 2, 3 and 4)
Time Frame: Pre-discharge, 30-day, and 1-year
|
As per VARC-3 defined criteria
|
Pre-discharge, 30-day, and 1-year
|
Bleeding (Type 3 and 4)
Time Frame: Pre-discharge, 30-day, 1-year, 3-year, and 5-year
|
As per VARC-3 defined criteria
|
Pre-discharge, 30-day, 1-year, 3-year, and 5-year
|
Moderate or severe prosthetic valve regurgitation
Time Frame: Pre-discharge, 30-day, 1-year, 3-year, 5-year, 7-year, and 10-year
|
As per VARC-3 defined criteria
|
Pre-discharge, 30-day, 1-year, 3-year, 5-year, 7-year, and 10-year
|
New permanent pacemaker implantation (As per VARC-3 defined criteria)
Time Frame: Pre-discharge, 30-day, 6-month, 1-year, 2-year, 3-year, 4-year, 5-year, 7-year, and 10-year
|
o New PPI rates will be analysed further based on the patient's history of left and/or right bundle branch block.
|
Pre-discharge, 30-day, 6-month, 1-year, 2-year, 3-year, 4-year, 5-year, 7-year, and 10-year
|
Conduction disturbances and arrhythmias
Time Frame: Pre-discharge, 30-day, 1-year, 3-year, and 5-year
|
As per VARC-3 defined criteria
|
Pre-discharge, 30-day, 1-year, 3-year, and 5-year
|
Device success
Time Frame: Pre-discharge and 30-day
|
As per VARC-3 defined criteria
|
Pre-discharge and 30-day
|
Early safety at 30 days
Time Frame: 30-day
|
As per VARC-3 defined criteria
|
30-day
|
Clinical efficacy at 30 days
Time Frame: After 30 days of index procedure
|
As per VARC-3 defined criteria
|
After 30 days of index procedure
|
Valve related long-term clinical efficacy
Time Frame: 5-years, 7 years and 10 years
|
As per VARC-3 defined criteria
|
5-years, 7 years and 10 years
|
Vascular and access related complications
Time Frame: Pre-discharge, 30-day, and 1-year
|
As per VARC-3 defined criteria
|
Pre-discharge, 30-day, and 1-year
|
Major vascular complications
Time Frame: Pre-discharge, 30-day, and 1-year
|
As per VARC-3 defined criteria
|
Pre-discharge, 30-day, and 1-year
|
Functional improvement from baseline as measured per
Time Frame: [Time frame: Baseline (pre-procedure), 30-day, 1-year, 3-year, 5-year, 7-year, and 10-year], [Time frame: Baseline (pre-procedure), 30-day and 1-year]
|
New York Heart Association (NYHA) functional classification [Time frame: Baseline (pre-procedure), 30-day, 1-year, 3-year, 5-year, 7-year, and 10-year] Six-minute walk test [Time frame: Baseline (pre-procedure), 30-day and 1-year]
|
[Time frame: Baseline (pre-procedure), 30-day, 1-year, 3-year, 5-year, 7-year, and 10-year], [Time frame: Baseline (pre-procedure), 30-day and 1-year]
|
Echocardiographic endpoints
Time Frame: Baseline, pre-discharge, 30-day, 1-year, 3-year, 5-year, 7-year, and 10-year
|
|
Baseline, pre-discharge, 30-day, 1-year, 3-year, 5-year, 7-year, and 10-year
|
Bioprosthetic valve deterioration
Time Frame: Pre-discharge, 30-day, 1-year, 3-year, and 5-year
|
As per VARC-3 defined criteria
|
Pre-discharge, 30-day, 1-year, 3-year, and 5-year
|
Patient-prosthesis mismatch
Time Frame: Pre-discharge, 30-day, and 1-year
|
Severity patient-prosthesis-mismatch will be based on following
|
Pre-discharge, 30-day, and 1-year
|
Length of index hospital stay
Time Frame: At discharge
|
o Number of days from hospital admission to discharge.
|
At discharge
|
Re-hospitalization
Time Frame: 30-day, 1-year, 3-year, and 5-year
|
As per VARC-3 defined criteria
|
30-day, 1-year, 3-year, and 5-year
|
Health status as evaluated by Quality of Life questionnaires
Time Frame: Baseline (pre-procedure), 30-day, and 1-year
|
o 12-Item Short Form Survey (SF-12)
|
Baseline (pre-procedure), 30-day, and 1-year
|
Valve thrombosis
Time Frame: 30-day, 1-year, 3-year, and 5-year
|
o Valve thrombosis as per VARC-2 is any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment.
Note that valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve-related should not be reported as valve thrombosis.
|
30-day, 1-year, 3-year, and 5-year
|
Coronary obstruction requiring intervention
Time Frame: Pre-discharge
|
As per VARC-3 defined criteria
|
Pre-discharge
|
Valve malpositioning
Time Frame: Pre-discharge
|
As per VARC-3 defined criteria
|
Pre-discharge
|
Conversion to open surgery
Time Frame: Pre-discharge
|
As per VARC-3 defined criteria
|
Pre-discharge
|
Unplanned use of mechanical circulatory support (cardiopulmonary bypass (CPB), extracorporeal membrane oxygenation (ECMO), transcatheter pumps or intra-aortic balloon pump (IABP)
Time Frame: Pre-discharge
|
As per VARC-3 defined criteria
|
Pre-discharge
|
Implantation of multiple (>1) transcatheter valves during the index hospitalization
Time Frame: Index-procedure
|
As per VARC-3 defined criteria
|
Index-procedure
|
Cardiac structural complications
Time Frame: 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
|
As per VARC-3 defined criteria
|
30 days, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
|
Ventricular septal perforation
Time Frame: Pre-discharge
|
o Angiographic or echocardiographic evidence of a new septal perforation during or after the TAVI procedure
|
Pre-discharge
|
New onset of atrial fibrillation or atrial flutter
Time Frame: Pre-discharge, 30-day, 1-year, 3-year, and 5-year
|
As per VARC-3 defined criteria
|
Pre-discharge, 30-day, 1-year, 3-year, and 5-year
|
Technical success
Time Frame: Post-procedure
|
As per VARC-3 defined criteria
|
Post-procedure
|
Myocardial Infarction
Time Frame: Pre-discharge, 30-day, 1-year, 3-year, and 5-year
|
As per VARC-3 defined criteria
|
Pre-discharge, 30-day, 1-year, 3-year, and 5-year
|
Endocarditis
Time Frame: 30-day, 1-year, 3-year, and 5-year
|
As per VARC-3 defined criteria
|
30-day, 1-year, 3-year, and 5-year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Andreas Baumbach, MD,FESC,FRCP, Barts Heart Center, London, UK
- Study Director: Patrick W. Serruys, MD,PhD,FACC,FESC, National University of Ireland, Galway, Ireland
Publications and helpful links
General Publications
- Kawashima H, Soliman O, Wang R, Ono M, Hara H, Gao C, Zeller E, Thakkar A, Tamburino C, Bedogni F, Neumann FJ, Thiele H, Abdel-Wahab M, Morice MC, Webster M, Rosseel L, Mylotte D, Onuma Y, Wijns W, Baumbach A, Serruys PW. Rationale and design of a randomized clinical trial comparing safety and efficacy of myval transcatheter heart valve versus contemporary transcatheter heart valves in patients with severe symptomatic aortic valve stenosis: The LANDMARK trial. Am Heart J. 2021 Feb;232:23-38. doi: 10.1016/j.ahj.2020.11.001. Epub 2020 Nov 6.
- Kawashima H, Wang R, Mylotte D, Jagielak D, De Marco F, Ielasi A, Onuma Y, den Heijer P, Terkelsen CJ, Wijns W, Serruys PW, Soliman O. Quantitative Angiographic Assessment of Aortic Regurgitation after Transcatheter Aortic Valve Implantation among Three Balloon-Expandable Valves. Glob Heart. 2021 Mar 19;16(1):20. doi: 10.5334/gh.959.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MLS/MYV-2/LANDMARK
- 2020-000137-40 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Valve Stenosis
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
The Medicines CompanyCompletedTranscatheter Aortic Valve Replacement | Aortic Valve Replacement | Severe Aortic StenosisNetherlands, Germany, United Kingdom, Canada, France, Italy, Switzerland
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Edwards LifesciencesCompletedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Sorin Group USA, Inc.TerminatedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
BC Centre for Improved Cardiovascular HealthEdwards LifesciencesUnknownTranscatheter Aortic Valve Implantation | Severe Aortic StenosisCanada
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
Hospices Civils de LyonRecruiting
Clinical Trials on Myval THV Series
-
Meril Life Sciences Pvt. Ltd.RecruitingAortic Valve StenosisSlovenia, Spain, Turkey, Italy, Netherlands, Estonia, Poland
-
Sahajanand Medical Technologies LimitedQmed Consulting A/SNot yet recruiting
-
Edwards LifesciencesRecruitingPulmonary Valve Insufficiency | Complex Congenital Heart Defect | Dysfunctional RVOT Conduit | Pulmonary Valve DegenerationUnited States
-
Edwards LifesciencesNot yet recruitingMitral Regurgitation | Mitral Valve Disease | Mitral Stenosis
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
Edwards LifesciencesRecruitingAortic Stenosis, SevereUnited States, Australia, New Zealand, Canada
-
Edwards LifesciencesRecruitingPulmonary Valve Insufficiency | Complex Congenital Heart Defect | Dysfunctional RVOT Conduit | Pulmonary Valve Degeneration | Pulmonary Valve; ObstructionUnited States
-
Edwards LifesciencesActive, not recruitingHeart Diseases | Cardiovascular Diseases | Congenital Abnormalities | Heart Defects, Congenital | Pulmonary Valve Insufficiency | Pulmonary Valve StenosisUnited States
-
Edwards LifesciencesRecruitingAortic Valve Stenosis | Aortic Valve InsufficiencyUnited States, Canada
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia